Glycoprotein VI antibodies and methods of use thereof
The present invention describes antibodies generated against platelet membrane glycoprotein VI (GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research, diagnostic and immunotherapeutic agents, in particular, as diagnostic and therapeutic agents for the detection and treatment of thrombosis and other vascular diseases.
1. A method for detecting a soluble glycoprotein VI (GPVI) polypeptide or peptide in a sample, comprising the steps of:
a. contacting the sample with a first monoclonal antibody specific for the GPVI polypeptide or peptide,
b. capturing the GPVI polypeptide or peptide in the sample with the first monoclonal antibody,
c. contacting the sample with a second monoclonal antibody specific for the GPVI polypeptide or peptide, and
d. detecting the captured GPVI polypeptide or peptide with the second monoclonal antibody,
wherein the first and second monoclonal antibodies inhibit collagen-induced platelet aggregation at an IC 50 of less than 7μg/ml, wherein the IC 50 is determined using a concentration of collagen that induces 70-90% platelet aggregation within 5 minutes of its contact with platelets in a platelet aggregation assay, and wherein the first and second monoclonal antibodies specifically bind to the GPVI polypeptide or peptide at a Kd of lower than 10 −8 M, and wherein the first and second monoclonal antibodies are different, and wherein the first monoclonal antibody and second monoclonal antibody are selected from OM1 (ATCC No. PTA-5938), OM2 (ATCC No. PTA-5939), OM3 (ATCC No. PTA-5940), and OM4 (ATCC No. PTA-5941).
2. The method of claim 1 , wherein the first monoclonal antibody is OM1 (ATCC No. PTA-5938) and the second monoclonal antibody is OM2 (ATCC No. PTA-5939).
3. The method of claim 1 , wherein the first monoclonal antibody is immobilized.
4. The method of claim 1 , wherein the second monoclonal antibody is labeled.
5. The method of claim 4 , wherein the label is selected from biotin digoxigenin, fluorophores, metal complexes and enzymes.
6. The method of claim 1 , wherein the sample is plasma or serum.
7. The method of claim 1 , wherein the method is capable of detecting at least 0.2 ng/ml of GPVI polypeptide or peptide in the sample.
8. A method for quantifying a soluble glycoprotein VI (GPVI) polypeptide or peptide in a sample, comprising the steps of:
a. contacting the sample with a first monoclonal antibody specific for the GPVI polypeptide or peptide,
b. capturing the GPVI polypeptide or peptide in the sample with the first monoclonal antibody,
c. contacting the sample with a second monoclonal antibody specific for the GPVI polypeptide or peptide, and
d. quantifying the captured GPVI polypeptide or peptide with the second monoclonal antibody,
wherein the first and second monoclonal antibodies inhibit collagen-induced platelet aggregation at an IC 50 of less than 7μg/ml, wherein the IC 50 is determined using a concentration of collagen that induces 70-90% platelet aggregation within 5 minutes of its contact with platelets in a platelet aggregation assay, and wherein the first and second monoclonal antibodies specifically bind to the GPVI polypeptide or peptide at a Kd of lower than 10 −8 M, and wherein the first and second monoclonal antibodies are different, and wherein the first monoclonal antibody and second monoclonal antibody are selected from OM1 (ATCC No. PTA-5938), OM2 (ATCC No. PTA-5939), OM3 (ATCC No. PTA-5940), and OM4 (ATCC No. PTA-5941).
9. The method of claim 8 , wherein the first monoclonal antibody is OM1 (ATCC No. PTA-5938) and the second monoclonal antibody is OM2 (ATCC No. PTA-5939).
10. The method of claim 8 , wherein the first monoclonal antibody is immobilized.
11. The method of claim 8 , wherein the second monoclonal antibody is labeled.
12. The method of claim 11 , wherein the label is selected from biotin digoxigenin, fluorophores, metal complexes and enzymes.
13. The method of claim 8 , wherein the sample is plasma or serum.
14. The method of claim 8 , wherein the method is capable of quantifying at least 0.2 ng/ml of GPVI polypeptide or peptide in the sample.
15. An assay system for detecting or quantifying a soluble glycoprotein VI (GPVI) polypeptide or peptide in a sample, comprising a first and a second monoclonal antibody specific for the GPVI polypeptide or peptide, and using the method steps of:
a. contacting the sample with a first monoclonal antibody specific for a GPVI polypeptide or peptide,
b. capturing the GPVI polypeptide or peptide in the sample with the first monoclonal antibody,
c. contacting the sample with a second monoclonal antibody specific for a GPVI polypeptide or peptide, and
d. detecting or quantifying the captured GPVI polypeptide or peptide with the second monoclonal antibody,
wherein the first and second monoclonal antibodies inhibit collagen-induced platelet aggregation at an IC 50 of less than 7μg/ml, wherein the IC 50 is determined using a concentration of collagen that induces 70-90% platelet aggregation within 5 minutes of its contact with platelets in a platelet aggregation assay, and wherein the first and second monoclonal antibodies specifically bind to the GPVI polypeptide or peptide at a Kd of lower than 10 −8 M, and wherein the first and second monoclonal antibodies are different, and wherein the first monoclonal antibody and second monoclonal antibody are selected from OM1 (ATCC No. PTA-5938), OM2 (ATCC No. PTA-5939), OM3 (ATCC No. PTA-5940), and OM4 (ATCC No. PTA-5941).
16. The assay system of claim 15 , wherein the first monoclonal antibody is OM1 (ATCC No. PTA-5938) and the second monoclonal antibody is OM2 (ATCC No. PTA-5939).
17. The assay system of claim 15 , wherein the first monoclonal antibody is immobilized.
18. The assay system of claim 15 , wherein the second monoclonal antibody is labeled.
19. The assay system of claim 18 , wherein the label is selected from biotin, digoxigenin, fluorophores, metal complexes and enzymes.
20. The assay system of claim 15 , wherein the sample is plasma or serum.
21. The assay system of claim 15 , wherein the assay system is capable of detecting or quantifying at least 0.2 ng/ml of GPVI polypeptide or peptide in the sample.